Hanmi Pharmaceutical said that it has confirmed its global competitiveness for its obesity, diabetes and nonalcoholic steatohepatitis (NASH) treatment candidates, at the 79th American Diabetes Association (ADA) held in San Francisco, Calif.
The company published 12 research results in three posters session and other presentations for three bio-drug candidate materials that the company has been developing using the company’s patented Lapscovery technology.
|Hanmi Pharmaceutical Research Lab Director Choi In-young (right) presents a poster session on LAPSGlucagon Analog during the ADA 2019 at the Moscone Center in San Francisco, Calif., from June 7-11|
The three new biopharmaceutical drugs announced at the ADA are efpeglenatide, licensed out to Sanofi by Hanmi, “LAPSTriple Agonist,” a NASH therapeutic drug candidate, and “LAPSGlucagon Analog,” obesity and rare disease treatment.
During this year’s ADA, Hanmi and Sanofi jointly presented various efficacies, such as blood sugar and weight control of epeglenetide.
Hanmi has raised the expectation for commercialization of LAPSTriple agonist as a treatment for NASH, which was an area where other global pharmaceutical companies had a hard time succeeding in.
Hanmi has also proven excellent weight loss and metabolism improvement effects in the long-term administration of LAPSGlucagon Analog in an obese animal model and confirmed the possibility of developing it as a next-generation obesity treatment drug. LAPSGlucagon Analog received orphan drug designation (ODD) from the U.S. Food and Drug Administration in February last year.
“This conference was a good opportunity for the company to showcase its global competitiveness of various bio-drugs applying LABSCOVERY, a Hanmi Pharma platform technology, on the global stage,” Hanmi CEO Kwon Se-chang said. “We will step up the clinical development of Lapscovery-applied pipeline and expand our treatment area by making the most of the platform technology.”
<© Korea Biomedical Review, All rights reserved.>